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Abstract 
Decline in respiratory function in patients with DMD starts during early teenage years and leads to early morbidity and mortality. Published 
evidence of efficacy for idebenone on respiratory function outcomes is currently limited to 12 months of follow-up time. Here we report 
data collected as retrospective cohort study (SYROS) from 18 DMD patients not using glucocorticoids who were treated with idebenone 
(900 mg/day) under Expanded Access Programs (EAPs). The objective was to assess the long-term respiratory function evolution for periods 
On-Idebenone compared to periods Off-Idebenone in the same patients. The mean idebenone exposure in the EAPs was 4.2 (range 2.4–6.1) 
years. The primary endpoint was the annual change in forced vital capacity percent of predicted (FVC%p) compared between Off-Idebenone 
and On-Idebenone periods. The annual rate of decline in FVC%p was reduced by approximately 50% from −7.4% (95% CI: −9.1, −5.8) 
for the Off-Idebenone periods to −3.8% (95% CI: −4.8, −2.8) for the On-Idebenone periods ( N = 11). Similarly, annual change in peak 
expiratory flow percent of predicted (PEF%p) was −5.9% (95% CI: −8.0, −3.9) for the Off-Idebenone periods ( N = 9) and reduced to −1.9% 
(95% CI: −3.2, −0.7) for the On-Idebenone periods during the EAPs. The reduced rates of decline in FVC%p and PEF%p were maintained 
for several years with possible beneficial effects on the rate of bronchopulmonary adverse events, time to 10% decline in FVC%p and risk of 
hospitalization due to respiratory cause. These long-term data provide Class IV evidence to further support the disease modifying treatment 
effect of idebenone previously observed in randomized, controlled trials. 
© 2020 The Authors. Published by Elsevier B.V. 
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Duchenne muscular dystrophy (DMD) is characterized
by relentlessly progressive muscle weakness leading to
loss of motor function, cardiomyopathy, progressive spinal
abnormality, respiratory function decline and death in early
adulthood [1 , 2] . Respiratory function decline, a predominant
cause of early mortality in DMD, results from the underlying
weakness and degeneration of the respiratory muscle groups,
notably the diaphragm, the intercostal and chest wall muscles,
leading to impaired respiratory muscle strength. Respiratory
function decline in DMD patients is currently irreversible
and all patients will ultimately develop chronic respiratory
insufficiency and require ventilator support [3 , 4] . There is
currently no therapeutic intervention specifically approved
for the treatment of respiratory dysfunction in patients with
DMD. 
In DMD respiratory function can be reliably measured as
peak expiratory flow (PEF) or forced vital capacity (FVC),
both expressed as percent of predicted (PEF%p, FVC%p)
(reviewed in [4–6] ). Abnormal respiratory function, defined
as PEF%p or FVC%p falling below 80% of normal, typically
occurs at around 10–14 years of age and coincides with the
time of loss of ambulation. Thereafter, and over the course of
about 10 years both PEF%p and FVC%p follow a co-linear
decline [6–10] (reviewed in [4 , 11] ). 
Idebenone, a synthetic short-chain benzoquinone, improves
mitochondrial function, restores ATP production and
catalytically reduces reactive oxygen species, thereby
addressing the muscle cell damaging consequences of
dystrophin deficiency (as reviewed in [12] ). Idebenone
showed a cardio-protective effect and improved exercise
performance in the dystrophin-deficient mdx mouse model of
DMD [13] . 
A proof-of-concept, randomized, placebo-controlled
phase 2 trial of 12 months duration in 21 DMD patients
(DELPHI trial) provided initial evidence that idebenone has
the potential to slow loss of respiratory function [14 , 15] .
A confirmatory phase 3, randomized, placebo-controlled
trial (DELOS trial) specifically investigated the efficacy of
idebenone on respiratory function outcomes in 64 DMD
patients (age 10–18 years, 92% non-ambulatory at baseline)
who discontinued glucocorticoid (GC) use at least one year
prior to study start [16 , 17] . Eligible patients had abnormal
respiratory function, defined as PEF%p at baseline of less
than 80%. Patients received idebenone ( N = 31; 900 mg daily)
or matching placebo ( N = 33) for 12 months. The trial met its
primary endpoint and demonstrated a statistically significant
and clinically relevant reduction in the loss of PEF%p
[16] at 12 months. The outcome of the primary endpoint was
robust across pre-specified study populations and supported
by consistent findings for changes in other respiratory
function measures [16 , 18–20] and clinical outcomes
[21] . 
At present, long-term data from the treatment of DMD
patients with idebenone are still sparse, precluding thenterpretation whether the treatment effect of idebenone
bserved in randomized controlled trials of 12 months
uration may persist over prolonged periods of time.
herefore, we collected data from patients receiving
debenone through Expanded Access Programs (EAPs)
ollowing their completion of the DELOS trial. Here we
eport the outcome of this retrospective cohort study (SYROS)
ith patients followed under routine clinical care, with
he objective to assess the long-term respiratory function
volution during idebenone treatment compared to idebenone-
ree periods in patients with DMD. 
. Methods 
.1. Collection of data from expanded access programs 
Requests by trial investigators were submitted to the
ponsor of the DELOS trial (Santhera Pharmaceuticals,
ratteln, Switzerland), to provide idebenone for patients
ho had previously completed the trial. According to such
equests, free of charge access to idebenone medication was
ubsequently governed by EAPs under applicable national
ules and regulations (DELOS-Named Patient Program
DELOS-NPP] or DELOS Compassionate Use Program
DELOS-CUP]). Treatment of patients with idebenone
2 ×150 mg tablets 3 times daily with meals; total daily dose
 tablets, 900 mg) according to the EAPs was under the sole
iscretion of the treating physician and data collection was
erformed according to standard of care clinical monitoring of
he patients. Data collected from these patients, including data
n respiratory function and disease progression/complications,
ere stored by the hospital responsible for the EAPs and are
onsidered data obtained under routine clinical care. 
The SYROS study protocol (describing the data collection
rocedure and analysis methods) and the Data Release
greement form were approved by the independent ethics
ommittees of all study sites involved before commencement
f this retrospective cohort study. The study was conducted
n compliance with the latest version of the Declaration
f Helsinki, with the current requirements for Good
harmacoepidemiology Practices (GPP Guideline 2015),
ood Pharmacovigilance Practices (GVP-Module VI) and
ith local laws and regulations. Available medical data
ollected under routine clinical care were recorded at the
nvestigator sites. Data collected from the time the subject had
ompleted the last visit (at month 12) of the DELOS trial until
he most recent hospital visit available at the time of this data
ollection were retrieved from the patients’ medical records
nd entered in the case record form by the site investigator.
nly after patients had signed the Data Release Agreement,
oded data using the former DELOS patient number as
atient identifier for the present study were collected. The
rst patient’s Data Release Agreement form was signed on
9 August 2017. The data collected covers a period from 30
ugust 2010 to 13 March 2018. 
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Fig. 1. Illustration of terminology used in this study 
Schematic presentation; x-axis is not to scale for time. EAP: expanded access program. Double borders indicate periods preceding the initiation of treatment 





























































p  .2. Patient eligibility 
Patients were included in the study if all of the following
nclusion criteria were met: (i) patient had completed the
ELOS trial (clinicaltrials.gov ID: NCT01027884; [16] ) and
as currently under the medical care of a study site with an
ngoing EAP; (ii) patient had taken idebenone as part of the
APs available in these countries, following his participation
n the DELOS trial, and (iii) patient had provided a signed
ata Release Agreement. There were no defined exclusion
riteria. For this study long-term respiratory outcome data
rom 18 patients with DMD treated with idebenone between
ctober 2011 and March 2018 were collected and analyzed. 
.3. Study objectives 
The primary objective was to evaluate the long-term
volution of respiratory function during idebenone treatment
On-Idebenone), compared to the evolution during idebenone-
ree periods (Off-Idebenone) in patients with DMD. The
econdary objective was to evaluate the effect of idebenone
n clinically relevant disease milestones, medical events,
reatment interventions and other relevant medications. 
.4. Data analysis and statistical methods 
Data were transcribed from the case record form to an
lectronic database hosted by 4Pharma (Turku, Finland). The
atabase was locked on 01 June 2018. Data from the intent-
o-treat (ITT) data set are reported here. The ITT data analysis
et included all patients who were included in the ITT
opulation of the DELOS study and were enrolled to the
resent study under national EAPs. The data analysis was conducted according to a Statistical
nalysis Plan (SAP), which was finalized prior to data base
ock. The SAP was written in a blinded manner without
aving any access to the SYROS study data. Data from
oth the DELOS trial and from the present study were
sed to evaluate the evolution of respiratory function under
ong-term idebenone treatment. The terminology used in
his report is illustrated in Fig. 1 . On-Idebenone treatment
eriods were defined as any periods of time when patients
ither received idebenone during the randomized DELOS trial
i.e., the idebenone treatment group of DELOS) or during the
APs collected in the present SYROS study. Idebenone free
eriods, referred to as Off-Idebenone periods, were defined as
ny periods of time when patients did not receive idebenone,
ither during the randomized DELOS trial (i.e., the placebo
roup of DELOS) or after the completion of DELOS and
ollected in the present SYROS study. 
Respiratory function outcomes, forced vital capacity (FVC)
nd peak expiratory flow (PEF), were normalized to percent
f predicted (%p) as previously described [16] . 
To calculate the annual change in FVC%p and PEF%p,
hree data points from respiratory function assessments
baseline and at least two post-baseline assessments at
east 6 months apart) were required for an analysis
eriod to be deemed evaluable. A patient may have had
emporary interruptions during the idebenone treatment while
articipating in the EAP program. Any interruption of
debenone treatment of less than 10% of the total duration
f the On-Idebenone treatment periods were not considered
s clinically relevant (see below). For the primary analysis
f respiratory function change, the longest consecutive On-
debenone period during the EAPs was compared to the
receding evaluable period, either to an On-Idebenone period
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Fig. 2. By patient On-Idebenone and Off-Idebenone treatment periods and time points of respiratory function (FVC) assessments during DELOS and SYROS 
studies 
By patient treatment assignment, On-Idebenone or Off-Idebenone, is color coded by orange and gray bars respectively. Patients are grouped into comparison 
“On-On” idebenone and “Off-On” idebenone according the procedure described in methods. The time point when 12 of 18 patients started non-invasive 
























































in the DELOS study (comparison “On-On” Idebenone) or an
Off-Idebenone period before the EAPs (comparison “Off-On”
Idebenone) ( Fig. 1 ). 
The annual change of respiratory function measures
within each period (Off-Idebenone or On-Idebenone) was
estimated using random coefficient regression models, applied
separately for each analysis period. The random coefficient
regression model included the respiratory function values
analyzed (FVC%p, PEF%p) as response data, the baseline
value as a covariate and the assessment time (years since
the baseline) as a factor. The model included random slopes
and intercepts. The annual changes in respiratory function
outcomes (FVC%p, PEF%p) were estimated from the models
along with standard error of the mean (SEM) and 95%
confidence intervals (95% CI). 
Time to event analyses were conducted using Kaplan–
Meier methods and Cox models (for time to first event)
and with mean cumulative function estimates based on
proportional means models (for cumulative proportion of
events by time, allowing multiple events), similarly as
described in [21] . Statistical analyses were conducted using
SAS 9.4 (SAS Institute Inc., Cary, North Carolina, USA). 
2.5. Comparison to natural history data 
To further aid interpretation of the long-term treatment
effect of idebenone, annual change in FVC%p and PEF%p
during the longest consecutive On-Idebenone periods from
DELOS/SYROS were compared to data from patients
followed by the Cooperative International Neuromuscular
Research Group (CINRG) under the Duchenne natural history
study protocol (CINRG-DNHS study; NCT00468832 [6 , 22] ).
For this comparison, the annual rate of change in FVC%p andEF%p were calculated in 2-year bins for the On-Idebenone
eriods of DELOS/SYROS. For comparison, matched data
ere extracted from the CINRG-DNHS. Specifically, a
omparator dataset for each 2-year bin was generated with
xactly the same baseline FVC%p or PEF%p data (see
elow). All values available during the 2-year period after
rossing this baseline were used to calculate the annual rate
f change in the external comparator dataset by random
oefficient regression model as described above. 
. Results 
.1. Patient disposition 
In total, 27 patients previously enrolled into the Phase 3
ELOS trial, received idebenone under EAP programs in 6
ountries (Belgium, Germany, Netherlands, Spain, Sweden,
witzerland). Out of the 27 patients, two were excluded
ue to not signing the Data Release Agreement, one patient
ied during the EAP and 6 patients were excluded due to
arious other/administrative reasons (patient lost to follow-up
 N = 3), treating physician not available for the data collection
 N = 2) or the site was not included for administrative
easons ( N = 1)). The remaining 18 patients (from Belgium,
ermany, Netherlands and Switzerland) were included in the
YROS ITT population. For details on patient disposition, see
upplement Fig. 1. 
The Off-Idebenone and On-Idebenone periods from the
ELOS randomized controlled study and the SYROS data
ollection for each patient are summarized in Fig. 2 .
ltogether 11 of the 18 patients were Off-Idebenone before
debenone treatment under the EAPs while the remaining
 patients were On-Idebenone prior to starting the EAPs. 
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Table 1 
Summary of demographics, disease status and respiratory function data for 
the DELOS and SYROS ITT populations. 
DELOS ITT 
population N = 64 
SYROS ITT 





14.0, (10.1, 19.0) 
13.3 (2.7) 
12.9, (10.1, 18.5) 







Time since last glucocorticoid use, years 
n 
mean (SD) 
median, (minimum, maximum) 
36 
3.7 (2.1) 
3.5, (0.9, 8.9) 
11 
4.1 (1.9) 
4.2, (1.3, 6.9) 







Age at loss of ambulation, years 
n 
mean (SD) 
median, (minimum, maximum) 
59 
9.7 (1.5) 
9.5, (7.2, 14.3) 
15 
10.0 (1.7) 





53.0, (22.6, 96.4) 
58.7 (17.6) 





56.9, (29.1, 79.1) 
58.5 (10.2) 
59.1, (30.1, 77.7) 

















































































f  .2. Duration of treatment and follow-up time 
The mean exposure to idebenone in the EAPs was 4.2
ears (range 2.4–6.1 years) in the 18 patients. Before the
APs, the mean duration of follow-up for the 11 patients
ho were Off-Idebenone was 2.1 years (range 1.1–5.5 years),
hile mean exposure of idebenone was 1.0 years (range
.0–1.0) in the 7 patients who were On-Idebenone prior to
tarting the EAP. In total, the exposure to idebenone treatment
as 84.0 person years, consisting of 8.0 person years in the
ELOS study and 76.0 person years in the EAPs. The total
uration of Off-Idebenone periods was 32.3 person years,
onsisting of 10.0 person years during the placebo treatment
n the DELOS study and 22.4 person years of follow-up
s Off-Idebenone after DELOS. Details of the exposure and
uration of follow-up for the ITT population of the SYROS
tudy are summarized in Supplement Table 1. 
.3. Patient characterization 
Table 1 summarizes patient demographics and respiratory
unction status for the SYROS ITT population and the
ELOS ITT population at the time point of the DELOS
aseline (see Supplement Fig.2A). The mean age of the
8 patients enrolled into SYROS was 13.3 (range 10.1–
8.5) years, while the mean age of the total DELOS ITT
opulation was 14.3 (range 10.1–19.0) years. Whilst the
rotocol of the DELOS trial required that patients did not
se glucocorticoids (GCs), no such restriction applied for
he EAPs and there were two patients starting GC treatment
uring their participation in the EAPs. Twelve patients startedssisted ventilation (either nocturnal or daytime) during the
APs. Generally, the SYROS ITT population was comparable
o the DELOS ITT with regards to other demographic
arameters and respiratory function status. 
Similar comparative analysis of patient characteristics are
hown in Supplement Table 2 for patients who were Off-
debenone prior to the EAP ( N = 11) and those who were
n-Idebenone prior to the EAP ( N = 7), constituting the
Off-On” idebenone comparison and the “On-On” idebenone 
omparison, as illustrated in Supplement Fig. 2B 
.4. Primary efficacy analysis: annual change in FVC%p 
nd PEF%p while On-Idebenone in the EAPs, compared to 
eriod before the EAPs 
Fig. 3 illustrates the On-Idebenone and Off-Idebenone
reatment periods by patients for the primary analysis of
nnual change in FVC%p. In addition, the period while On-
debenone in the EAPs and the last evaluable period preceding
he EAPs are indicated by arrows. 
When the annual change in FVC%p was compared for
he “Off-On” idebenone group ( N = 11) the rate was reduced
y approximately 50% from −7.4% (95% CI: −9.1, −5.8)
or the Off-Idebenone period prior to the EAPs to −3.8%
95% CI: −4.8, −2.8) for the On-Idebenone period during
he EAP ( Fig. 4 A). As there were two patients starting GC
se during participation in the EAPs, a sensitivity analysis
as performed where the periods of GCs use were excluded
rom the analysis. The resulting annual rate of change for
VC%p was −7.4% (95% CI: −9.1, −5.6) for the Off-
debenone period and −3.9% (95% CI: −5.0, −2.9) for the
n-Idebenone period; these results were comparable to the
nalysis of the ITT population. In another sensitivity analysis
ll periods where patients ( N = 12) used assisted ventilation
either nocturnal or daytime) were excluded from the analysis.
he resulting annual rate of change for FVC%p was −6.8%
95% CI: −11.7, −2.0) for the Off-Idebenone period and
4.4% (95% CI: −6.6, −2.2) for the On-Idebenone period. 
The annual change in PEF%p, a secondary endpoint, was
5.9% (95% CI: −8.0, −3.9) for the Off-Idebenone periods
efore to the EAPs ( N = 9) and reduced to −1.9% (95% CI:
3.2, −0.7) for the On-Idebenone periods during the EAPs
 Fig. 4 B ) . 
When carrying out similar comparisons for the “On-On”
debenone group, the annual rate of decline in FVC%p
emained low both during the On-Idebenone periods before
he EAPs and during the On-Idebenone period during the
APs, with estimated rates of −0.7% (95% CI: −3.7, 2.2)
nd −3.9% (95% CI: −5.4, −2.3), respectively (Supplement
ig. 3A). Similar results were seen for the changes in PEF%p,
ith 1.3% (95% CI: −3.3, 5.8) for the On-Idebenone periods
efore the EAP and −1.3% (95% CI: −3.4, 0.8) for the On-
debenone periods during the EAPs (Supplement Fig. 3B). 
By-patient data presentations with individual slope 
stimates from the random coefficient regression model for
VC%p for the Off-Idebenone periods are compared to slopes
or the On-Idebenone periods as shown in Fig. 5 A and B.
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Fig. 3. Periods analyzed for annual change in FVC%p (primary efficacy outcome) 
Primary analysis for annual change in FVC%p for the SYROS ITT population. Treatment periods On-Idebenone (orange) and Off-Idebenone (gray) over time 
(years since DELOS baseline). Top part: “On-On” idebenone treatment comparison. Bottom part: “Off-On” idebenone treatment comparison by patient. Dotted 
arrows: periods before idebenone treatment under EAPs; solid arrows: EAPs treatment periods. 
Fig. 4. Annual rate of change for FVC%p (A) and PEF%p (B) between Off-Idebenone and On-Idebenone treatment periods 






























c  This representation illustrates the consistency of the result on
a by-patient level. Similar results were seen for the slopes for
PEF%p ( Fig. 5 C and D). 
3.5. Long-term evolution in change of FVC%p and PEF%p 
under idebenone treatment 
In a secondary analysis the annual changes in FVC%p and
PEF%p were compared in 2-year bins to assess how the rate
of change evolved with increasing treatment duration/follow-
up time ( Fig. 6 ). As shown, the annual decline in FVC%p
remained stable for the entire follow-up time during each of
the 2-year bins ( Fig. 6 A). A similar pattern was seen for
changes over time in PEF%p ( Fig. 6 B). 
To further interpret the annual change in FVC%p over the
6-year follow-up of DELOS/SYROS, we compared changes
in subgroups of untreated patients from the CINRG-DNHS
matched to the patients in the respective 2-year bins. As can
be seen in Fig. 6 , there is a consistently reduced annual ratef decline in FVC%p and PEF%p for patients receiving long-
erm idebenone treatment compared to matched untreated
atients from the natural history study. Furthermore, evaluable
ata were available during the Off-Idebenone periods in
ELOS/SYROS for two years. As shown in Fig. 6 (gray
ars), during this untreated period, the annual rate of decline
n FVC%p and PEF%p was comparable to the untreated
atients from the CINRG-DNHS and higher than in patients
ho were On-Idebenone. 
One possible limitation of this analysis is the fact that
he majority of patients in the SYROS study did not use GCs
hilst patients in the CINRG-DNHS were both GC users and
C non-users. 
.6. Efficacy of long-term idebenone treatment on clinically 
elevant outcomes 
Clinically relevant worsening in respiratory function is
ommonly defined as time to the first relative decline of 10%
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Fig. 5. Individual slopes over time by treatment period (Off-Idebenone, On-Idebenone). 
By-patient random-effects estimates from the random coefficient regression model, representing the estimated deviation from the mean slope. The individual 
estimates (along with the mean slope) are shown for change in FVC%p (A, B) ( N = 11) and PEF%p (C, D) ( N = 9). Slopes for the Off-Idebenone periods are 




















































l  n FVC%p from baseline. This analysis was conducted by
valuating the time to event during the longest consecutive
ff-Idebenone and On-Idebenone periods. Altogether 10
atients had a baseline value at the beginning of the longest
onsecutive Off-Idebenone period, while all 18 patients had
 baseline value at the beginning of the longest consecutive
n-Idebenone period, allowing for this analysis. The median
ime to the first 10% decline during the Off-Idebenone
eriod was 0.63 years compared with 1.72 years during
he On-Idebenone period (hazard ratio: 0.44), indicating that
debenone treatment prolonged the time to a 10% decline in
VC%p ( Fig. 7 ). 
We next investigated whether long-term treatment
ith idebenone could also influence the occurrence of
ronchopulmonary adverse events (BAEs), which constitute
linically relevant complications in patients with DMD. As
eported previously [21] , BAEs were classified as adverse
vents that involve the larynx, trachea, bronchi, lower airways
r lungs. During the Off-Idebenone periods, 5 patients
35.7%) reported 9 BAEs, i.e., 0.33 events per person-year
f follow-up. During the On-Idebenone periods, 6 patients
33.3%) reported 8 BAEs, i.e., 0.10 events per person year
f follow-up, representing a clear reduction in BAE events
nder idebenone treatment. The cumulative frequency of the
AEs as a function of time ( Fig. 8 ) demonstrated clearly
iverging trajectories for the cumulative occurrence of BAEsetween the On-Idebenone and Off-Idebenone treatment 
eriods (hazard ratio: 0.32). 
In line with a reduced frequency of BAEs, we also
bserved that patients during On-Idebenone periods required
ess systemic use of antibiotics. During the Off-Idebenone
eriods 3 patients (21.4%) reported 4 events of antibiotic use
i.e., 0.15 events per person year of follow-up) which was
igher than systemic antibiotic use reported for On-Idebenone
eriods with 3 patients (16.7%) reporting 3 events (i.e., 0.04
vents per person year of follow-up). 
As previous data from the DELOS trial also showed that
debenone treatment reduced the rate of hospitalizations due
o respiratory infections or other respiratory cause when
ompared to patients receiving placebo [21] , it was of
nterest to assess the efficacy of idebenone on the risk of
ospitalization due to respiratory cause also in the longer
erm. Table 2 provides a summary of events by category, the
vent rates per person year and number of patients during the
ff-Idebenone and On-Idebenone periods. 
The rates of hospitalizations due to respiratory infections
r related disorders were smaller for the On-Idebenone
eriods (0.06 events per person year) compared with Off-
debenone periods (0.15 events per person year), although
nterpretation is limited by the small number of events
eported. Hospitalizations due to any reason were also
ower in the On-Idebenone periods compared to the Off-
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Fig. 6. Comparison in the evolution of annual rates of change in respiratory function outcomes for patients during On-Idebenone and Off-Idebenone periods 
and matched groups of untreated patients. 
Annual rate of change in FVC%p (A) and PEF%p (B) are calculated from the longest consecutive On-Idebenone periods of the SYROS/DELOS studies 
(orange bars). Data from Off-Idebenone periods from SYROS/DELOS are shown for the first 2-year bins (gray bars), where such data were available. Data 
are estimated means (SEMs) from random coefficient regression models. Patients for the untreated natural history comparator groups were matched based on 
baseline FVC%p or PEF%p values respectively (black bars). Patient numbers/group are indicated and further details are provided in Supplement Table 3. 
Table 2 
Reasons for and frequency of hospitalization. 
Reason for hospitalization Longest consecutive Off-Idebenone period N = 14 Longest consecutive On-Idebenone period N = 18 
Number of 
events 
Event rate (events/ 
person year) 
N (%) Number of 
events 
Event rate (events/ 
person year) 
N (%) 
Respiratory infection or related disorder 4 0.15 2 (14.3) 5 0.06 5 (27.8) 










t  Idebenone periods (0.29 versus 0.48 events per person
year). 
4. Discussion 
This study analyses the decline of respiratory function in
patients with DMD not using GCs and treated with idebenonender routine clinical care. Specifically, compared to untreated
eriods, idebenone-treated periods were associated with a
educed risk of declining by 10% in FVC%p and a
educed risk of experiencing patient-relevant outcomes, such
s bronchopulmonary adverse events or hospitalizations due
o respiratory cause. Overall, these findings add long-
erm data to the previously reported body of evidence
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Fig. 7. Time to first decline of at least 10% (relative) in FVC%p by treatment. 
Kaplan–Meier analysis (proportional means regression analysis) of time to first decline in FVC%p by treatment period. N = 10 patients for Off-Idebenone 
periods; N = 18 patients for On-Idebenone periods. 
Fig. 8. Cumulative frequency plot for bronchopulmonary adverse events by treatment. 
Kaplan–Meier analysis (proportional means regression model) for cumulative frequency of bronchopulmonary adverse events (BAEs) by treatment. N = 14 












m  16 , 18 –21] , demonstrating that idebenone holds disease-
odifying therapeutic potential to preserve respiratory
unction. 
The present study is limited by the small sample size
 N = 18), which represents 28% (18 of 64) of all patients
andomized in the DELOS trial. The sample size wasoverned only by the legal/regulatory framework and treating
hysicians’ initiative to provide patients with unapproved 
edication under conditions of national Expanded Access
rograms. The limited sample size is partially compensated
y the extended follow-up time under which patients were
onitored under routine clinical care, providing data from 76






































































































T  person-years of idebenone treatment. To our knowledge, this
is the longest period of exposure reported to an investigational
drug in DMD outside that of GC use. Previously the longest
follow-up time was 188 weeks (3.6 years) in drisapersen
treated patients [23] and 180 weeks (3.5 years) in eteplirsen
treated patients [24] ; with 12 subjects followed-up in both
studies. 
Another limitation is that data were acquired during
standard of care assessment in the real-world setting [25] ,
and that no procedure insured the consistency of assessment
methods across the sites or the systematic collection of all
concomitant medication use, which could also have influenced
the observed effects. It is however important to highlight that
the frequency of FVC assessments was sufficiently regular to
allow analysis and interpretation of the primary endpoint of
the SYROS study, change in FVC%p. 
The possible impact of patients’ use of non-invasive
ventilation ( N = 12) or use of cough-assist devices cannot
be excluded in this follow up study. Such possible impact
was assessed in a sensitivity analysis excluding periods when
patients reported NIV use. The annual rate of change in
FVC%p for this sensitivity analysis was −6.8% for Off-
Idebenone periods compared to −4.4% for On-Idebenone
periods with overlapping confidence intervals. 
To ensure data integrity, the collection of patient data and
details of the analysis to be conducted was prospectively
planned and described in a study protocol and Statistical
Analysis Plan which was completed and signed off without
data at hand. 
In summary, these long-term data provide Class IV
evidence [26] to further support the disease modifying
treatment effect of idebenone previously observed in
randomized, controlled trials. 
Despite the limitations of this study, the difference
observed in the annual rate of decline in respiratory function
(FVC%p and PEF%p) between the Off-Idebenone and On-
Idebenone periods appears clinically relevant for two reasons:
(1) The reduced rate of decline in respiratory function and
the smaller number of bronchopulmonary complications
and hospitalization for respiratory events. Results from
this non-controlled data collection appear to be in line
with the results of the DELOS trial, that showed that
fewer patients in the idebenone group compared to the
placebo group experienced bronchopulmonary adverse
events and serious adverse events leading to hospital
admissions due to respiratory causes [21] . 
(2) Long-term treatment with idebenone reduced the annual
rate of decline in FVC%p by approximately 50% (from
−7.4% for Off-Idebenone periods to −3.8% for On-
Idebenone periods) for up to 6 years. A sustained
reduction in the rate of decline of FVC%p indicates a
potential therapeutic benefit as it could result in a delay
in the need for assisted ventilation. Such a delay would
be of unquestionable clinical benefit as demonstrated
in patient and caregiver surveys [27 , 28] , as it preserves
the quality of life of patients and caregivers [29] andreduces medical costs associated with non-invasive and
invasive ventilation [30] and warrants further evaluation.
Several questions remain to be assessed to fully explore the
herapeutic potential of idebenone in the treatment of DMD. A
tudy in younger, predominantly ambulant patients would be
seful to investigate the effect of idebenone on non-respiratory
uscle, and more specifically on upper limb function which
s the main function to preserve in patients with already
stablished respiratory involvement [10] . The combined effect
f idebenone and glucocorticoids on respiratory outcomes
s currently under investigation in a large randomized,
lacebo-controlled study (SIDEROS, clinical trials.gov ID:
CT02814019). 
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